Skip to main content

Abstract

It is doubtful that many in this room would quibble with the statement, in regard to warfarin dosage, that almost every physician appears to behave as if there were no published guidelines for prophylaxis and that he is, so to speak, “therapeutically on his own”. What this means in practical terms to individual patients in each of our own communities is that the therapeutic regimen offered depends on which physician is consulted. Moreover, within each category of practitioner, prophylaxis depends on the hospital entered, the service assigned, the specific attending physician responsible for the patient’s care, and, at some institutions, the house officer on duty at the time of admission. Private office and clinic outpatient management is no more standardized. In recognition of this absence of consensus it is hoped that several of the presentations to follow may provide some common ground concerning therapeutic regimens that will be of intrinsic value for decision making in cardiac and cerebral vascular disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. F.W. Schofield, A brief account of a disease of cattle simulating hemorrhagic septicaemia due to feeding sweet clover, Can Vet Rec 3:74(1922).

    Google Scholar 

  2. K. P. Link, Anticoagulant from spoiled sweet clover hay, Harvey Lect 39:162(1944).

    Google Scholar 

  3. A. J. Quick, The prothrombin in hemophilia and in obstructive jaundice, J Biol Chem, 109:lxxiii(1935).

    Google Scholar 

  4. J. B. Bingham, O. O. Meyer, and F.J. Pohle, Studies on the hemorrhagic agent 3,3′-methylenebis (4-Hydroxycoumarin). I. Its effect on the prothrombin and coagulation time of the blood of dogs and humans, Am J Med Sci, 202:563(1941).

    Article  CAS  Google Scholar 

  5. H. R. Butt, E.V. Allen, and J. L. Bollman, A preChapaution from spoiled sweet clover [3,3′-methylenebis-(4-hydroxycoumarin)] which prolongs coagulation and prothrombin time of the blood: preliminary report of experimental and clinical studies, Proc Staff Meet Mayo Clin, 16:388(1941).

    CAS  Google Scholar 

  6. A. Prandoni, and I. S. Wright, The anticoagulants heparin and the dicumarin -3, 3′-methylenebis-(4-hydroxycoumarin). Bull NY Acad Med, 18:433(1942).

    CAS  Google Scholar 

  7. P. B. Medawar, The Limits of Science, Harper and Row, New York (1984).

    Google Scholar 

  8. I. S. Wright, C. D. Marple, and D. F. Beck, Myocardial infarction: its clinical manifestations and treatment with anticoagulants. A study of 1031 cases, Grune and Stratton, New York (1954).

    Google Scholar 

  9. G. deTakats, Anticoagulant therapy in surgery, JAMA, 142:527(1950).

    Article  CAS  Google Scholar 

  10. D. A. Taberner, L. Poller, R. W. Burslem, and J. B. Jones, Oral anticoagulants controlled by the British comChapautive thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis. Br Med J 1:272(1978).

    Article  PubMed  CAS  Google Scholar 

  11. R. Hull, J. Hirsh, R. Jay, C. Carter, C. England, R. M. Gent, A. G. Turpie, D. McLoughlin, P. Dodd, M. Thomas, G. Raspob, and P. Ockefford, Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis, N Engl J Med 307:1676(1982).

    Article  PubMed  CAS  Google Scholar 

  12. C. W. Francis, V. J. Marder, C. M. Evarts, and S. Yaukoolbodi, Two-step warfarin therapy: prevention of postoperative venous thrombosis without excessive bleeding. JAMA 249:374(1983).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Springer Science+Business Media New York

About this chapter

Cite this chapter

Wessler, S. (1987). What’s the Dose?. In: Wessler, S., Becker, C.G., Nemerson, Y. (eds) The New Dimensions of Warfarin Prophylaxis. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-5985-3_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-5985-3_11

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4757-5987-7

  • Online ISBN: 978-1-4757-5985-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics